Clinical Trials Logo

Metaplasia clinical trials

View clinical trials related to Metaplasia.

Filter by:

NCT ID: NCT00136409 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)

Start date: May 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effects (good and bad) of Gleevec in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia and chronic myelomonocytic leukemia.

NCT ID: NCT00088231 Completed - Clinical trials for Acute Myelogenous Leukemia

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

Start date: July 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to find the highest safe doses of PTK 787 (vatalanib) and Gleevec (imatinib mesylate) that can be given to treat Chronic Myelogenous Leukemia-Blastic Phase (CML-BP), Refractory Acute Myelogenous Leukemia (AML), or Agnogenic Myeloid Metaplasia (AMM). Another goal is to see how effective this combination treatment is.

NCT ID: NCT00086125 Completed - Lymphoma Clinical Trials

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Start date: June 2004
Phase: Phase 2
Study type: Interventional

The purpose of this phase II study is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies.

NCT ID: NCT00081874 Completed - Leukemia Clinical Trials

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Start date: April 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to find the highest safe dose of RAD001 that can be given as a treatment for leukemia, mantle cell lymphoma, or myelofibrosis. Another goal is to learn how effective the dose that is found is as a treatment.

NCT ID: NCT00047190 Completed - Clinical trials for Primary Myelofibrosis

Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Start date: August 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of tipifarnib in treating patients who have myelofibrosis with myeloid metaplasia. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.